DGX: financial statements from SEC — TradeAlmanac

DGX

Quest Diagnostics Incorporated: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	2.90bn	2.82bn	2.76bn	2.65bn	2.49bn	2.40bn
Cost of revenue	1.95bn	1.87bn	1.82bn	1.79bn	1.68bn	1.59bn
Selling, general and administrative	504m	501m	486m	476m	448m	416m
Operating expenses	2.50bn	2.43bn	2.32bn	2.31bn	2.16bn	2.04bn
Operating income	399m	386m	438m	346m	330m	355m
Pre-tax income	334m	328m	384m	276m	296m	314m
Income tax	74m	77m	97m	59m	65m	74m
Net income	252m	245m	282m	220m	226m	229m
Earnings per share	2.27	2.18	2.51	1.97	2.01	2.05
Earnings per share, diluted	2.24	2.16	2.47	1.94	1.99	2.03
Weighted average shares	110m	112m	112m	111m	112m	111m
Weighted average shares, diluted	112m	113m	113m	113m	113m	112m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	393m	420m	432m	319m	188m	549m	764m	271m
Receivables	1.59bn	1.41bn	1.46bn

Cash flow

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Operating cash flow	278m	—	—	314m	—	—
Depreciation and amortisation	147m	142m	143m	140m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)